First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
- Author
- BIANCHINI, D1 2 ; OMLIN, A1 2 ; ZIVI, A1 2 ; BUCHBINDER, A1 2 ; RATHKOPF, D. E1 2 ; ATTARD, G1 2 ; SCHER, H. I1 2 ; DE BONO, J1 2 3 ; DANILA, D. C1 2 3 ; PEZARO, C1 2 ; LORENTE, D1 2 ; FERRALDESCHI, R1 2 ; MUKHERJI, D1 2 ; CRESPO, M1 2 ; FIGUEIREDO, I1 2 ; MIRANDA, S1 2 ; RIISNAES, R1 2
[1] Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, United Kingdom
[2] Memorial Sloan-Kettering Cancer Center (MSKCC) and Weill Cornell Medical College, Center for Prostate and Urologic Cancers, New York, NY, United States
[3] ENZON Pharmaceuticals Inc., Bridgewater, NJ, United States - Source
British journal of cancer. 2013, Vol 109, Num 10, pp 2579-2586, 8 p ; ref : 1 p
- CODEN
- BJCAAI
- ISSN
- 0007-0920
- Scientific domain
- Medical oncology
- Publisher
- Nature Publishing Group, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- EZN-4176 antisense oligonucleotide castration-resistant prostate cancer phase I clinical trial
- Keyword (fr)
- Cancer de la prostate Cancérologie Castration Essai clinique phase I Exon Homme Oligonucléotide antisens RNA messager Récepteur androgène Récepteur hormonal Résistance Traitement Acide nucléique verrouillé Cancer Pathologie de l'appareil génital mâle Pathologie de l'appareil urinaire Pathologie de la prostate Tumeur maligne
- Keyword (en)
- Prostate cancer Cancerology Castration Phase I trial Exon Human Antisense oligonucleotide Messenger RNA Androgen receptor Hormonal receptor Resistance Treatment Locked nucleic acid Cancer Male genital diseases Urinary system disease Prostate disease Malignant tumor
- Keyword (es)
- Cáncer de la próstata Cancerología Castración Ensayo clínico fase I Exón Hombre Oligonucleótido antisentido RNA mensajero Receptor andrógeno Receptor hormonal Resistencia Tratamiento Ácido nucléico bloqueado Cáncer Aparato genital macho patología Aparato urinario patología Prostata patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B14 Nephrology. Urinary tract diseases / 002B14D Tumors of the urinary system / 002B14D02 Urinary tract. Prostate gland
- Discipline
- Nephrology. Urinary tract diseases Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27952704
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/bjc.2013.619 
https://dx.doi.org/10.1038/bjc.2013.619
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.619\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2579\";s:8:\"\u0000*\u0000epage\";s:4:\"2586\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BIANCHINI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:8:\"OMLIN, A\";i:1;s:7:\"ZIVI, A\";i:2;s:13:\"BUCHBINDER, A\";i:3;s:14:\"RATHKOPF, D. E\";i:4;s:9:\"ATTARD, G\";i:5;s:11:\"SCHER, H. I\";i:6;s:10:\"DE BONO, J\";i:7;s:12:\"DANILA, D. C\";i:8;s:9:\"PEZARO, C\";i:9;s:10:\"LORENTE, D\";i:10;s:15:\"FERRALDESCHI, R\";i:11;s:11:\"MUKHERJI, D\";i:12;s:9:\"CRESPO, M\";i:13;s:13:\"FIGUEIREDO, I\";i:14;s:10:\"MIRANDA, S\";i:15;s:11:\"RIISNAES, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.619\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2579\";s:8:\"\u0000*\u0000epage\";s:4:\"2586\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BIANCHINI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:8:\"OMLIN, A\";i:1;s:7:\"ZIVI, A\";i:2;s:13:\"BUCHBINDER, A\";i:3;s:14:\"RATHKOPF, D. E\";i:4;s:9:\"ATTARD, G\";i:5;s:11:\"SCHER, H. I\";i:6;s:10:\"DE BONO, J\";i:7;s:12:\"DANILA, D. C\";i:8;s:9:\"PEZARO, C\";i:9;s:10:\"LORENTE, D\";i:10;s:15:\"FERRALDESCHI, R\";i:11;s:11:\"MUKHERJI, D\";i:12;s:9:\"CRESPO, M\";i:13;s:13:\"FIGUEIREDO, I\";i:14;s:10:\"MIRANDA, S\";i:15;s:11:\"RIISNAES, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.619\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.619\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2579\";s:8:\"\u0000*\u0000epage\";s:4:\"2586\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BIANCHINI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:8:\"OMLIN, A\";i:1;s:7:\"ZIVI, A\";i:2;s:13:\"BUCHBINDER, A\";i:3;s:14:\"RATHKOPF, D. E\";i:4;s:9:\"ATTARD, G\";i:5;s:11:\"SCHER, H. I\";i:6;s:10:\"DE BONO, J\";i:7;s:12:\"DANILA, D. C\";i:8;s:9:\"PEZARO, C\";i:9;s:10:\"LORENTE, D\";i:10;s:15:\"FERRALDESCHI, R\";i:11;s:11:\"MUKHERJI, D\";i:12;s:9:\"CRESPO, M\";i:13;s:13:\"FIGUEIREDO, I\";i:14;s:10:\"MIRANDA, S\";i:15;s:11:\"RIISNAES, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.619\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2579\";s:8:\"\u0000*\u0000epage\";s:4:\"2586\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BIANCHINI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:8:\"OMLIN, A\";i:1;s:7:\"ZIVI, A\";i:2;s:13:\"BUCHBINDER, A\";i:3;s:14:\"RATHKOPF, D. E\";i:4;s:9:\"ATTARD, G\";i:5;s:11:\"SCHER, H. I\";i:6;s:10:\"DE BONO, J\";i:7;s:12:\"DANILA, D. C\";i:8;s:9:\"PEZARO, C\";i:9;s:10:\"LORENTE, D\";i:10;s:15:\"FERRALDESCHI, R\";i:11;s:11:\"MUKHERJI, D\";i:12;s:9:\"CRESPO, M\";i:13;s:13:\"FIGUEIREDO, I\";i:14;s:10:\"MIRANDA, S\";i:15;s:11:\"RIISNAES, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/bjc.2013.619\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:9:\"\u0000*\u0000jtitle\";s:25:\"British journal of cancer\";s:9:\"\u0000*\u0000stitle\";s:13:\"Br. j. cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"2579\";s:8:\"\u0000*\u0000epage\";s:4:\"2586\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0007-0920\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"BIANCHINI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:8:\"OMLIN, A\";i:1;s:7:\"ZIVI, A\";i:2;s:13:\"BUCHBINDER, A\";i:3;s:14:\"RATHKOPF, D. E\";i:4;s:9:\"ATTARD, G\";i:5;s:11:\"SCHER, H. I\";i:6;s:10:\"DE BONO, J\";i:7;s:12:\"DANILA, D. C\";i:8;s:9:\"PEZARO, C\";i:9;s:10:\"LORENTE, D\";i:10;s:15:\"FERRALDESCHI, R\";i:11;s:11:\"MUKHERJI, D\";i:12;s:9:\"CRESPO, M\";i:13;s:13:\"FIGUEIREDO, I\";i:14;s:10:\"MIRANDA, S\";i:15;s:11:\"RIISNAES, R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BJCAAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:183:\"First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:23:\"Nature Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
